#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=3. Discussion
1-1	0-2	3.	_	_	_	_
1-2	3-13	Discussion	abstract	new	_	_

#Text=The aim of this study was to elucidate the rMnSOD-dependent nSMase changes and their role in the protective-preventive effect from ionizing radiation in the brain .
2-1	14-17	The	abstract[2]	new[2]	coref	10-6[62_2]
2-2	18-21	aim	abstract[2]	new[2]	_	_
2-3	22-24	of	abstract[2]	new[2]	_	_
2-4	25-29	this	abstract[2]|abstract[3]	new[2]|new[3]	coref	10-1[61_3]
2-5	30-35	study	abstract[2]|abstract[3]	new[2]|new[3]	_	_
2-6	36-39	was	_	_	_	_
2-7	40-42	to	_	_	_	_
2-8	43-52	elucidate	_	_	_	_
2-9	53-56	the	abstract[4]|abstract[5]	new[4]|new[5]	_	_
2-10	57-73	rMnSOD-dependent	abstract[4]|abstract[5]	new[4]|new[5]	_	_
2-11	74-80	nSMase	abstract[4]|abstract[5]	new[4]|new[5]	_	_
2-12	81-88	changes	abstract[4]|abstract[5]	new[4]|new[5]	_	_
2-13	89-92	and	abstract[5]	new[5]	_	_
2-14	93-98	their	abstract[5]|abstract[6]	new[5]|new[6]	coref	8-5[44_6]
2-15	99-103	role	abstract[5]|abstract[6]	new[5]|new[6]	_	_
2-16	104-106	in	_	_	_	_
2-17	107-110	the	abstract[7]	new[7]	coref	7-1[38_7]
2-18	111-132	protective-preventive	abstract[7]	new[7]	_	_
2-19	133-139	effect	abstract[7]	new[7]	_	_
2-20	140-144	from	abstract[7]	new[7]	_	_
2-21	145-153	ionizing	abstract[7]|abstract[8]	new[7]|new[8]	coref	3-5[12_8]
2-22	154-163	radiation	abstract[7]|abstract[8]	new[7]|new[8]	_	_
2-23	164-166	in	abstract[7]|abstract[8]	new[7]|new[8]	_	_
2-24	167-170	the	abstract[7]|abstract[8]|object[9]	new[7]|new[8]|new[9]	coref	7-6[0_9]
2-25	171-176	brain	abstract[7]|abstract[8]|object[9]	new[7]|new[8]|new[9]	_	_
2-26	177-178	.	_	_	_	_

#Text=Mice were exposed to a set of minor γ radiation and neutrons and a spectrum of neutrons , simulating the radiation levels to which cosmonauts will be exposed during deep-space , long-term missions .
3-1	179-183	Mice	animal	new	_	_
3-2	184-188	were	_	_	_	_
3-3	189-196	exposed	_	_	_	_
3-4	197-199	to	_	_	_	_
3-5	200-201	a	abstract[12]	giv[12]	coref	3-21[0_12]
3-6	202-205	set	abstract[12]	giv[12]	_	_
3-7	206-208	of	abstract[12]	giv[12]	_	_
3-8	209-214	minor	abstract[12]	giv[12]	_	_
3-9	215-216	γ	place|abstract[12]	new|giv[12]	coref	4-9
3-10	217-226	radiation	abstract[12]	giv[12]	_	_
3-11	227-230	and	_	_	_	_
3-12	231-239	neutrons	substance	new	coref	3-17
3-13	240-243	and	_	_	_	_
3-14	244-245	a	abstract[14]	new[14]	_	_
3-15	246-254	spectrum	abstract[14]	new[14]	_	_
3-16	255-257	of	abstract[14]	new[14]	_	_
3-17	258-266	neutrons	abstract[14]|substance	new[14]|giv	_	_
3-18	267-268	,	_	_	_	_
3-19	269-279	simulating	_	_	_	_
3-20	280-283	the	abstract[17]	new[17]	coref	14-9[100_17]
3-21	284-293	radiation	abstract|abstract[17]	giv|new[17]	coref	4-9[24_0]
3-22	294-300	levels	abstract[17]	new[17]	_	_
3-23	301-303	to	_	_	_	_
3-24	304-309	which	_	_	_	_
3-25	310-320	cosmonauts	person	new	_	_
3-26	321-325	will	_	_	_	_
3-27	326-328	be	_	_	_	_
3-28	329-336	exposed	_	_	_	_
3-29	337-343	during	_	_	_	_
3-30	344-354	deep-space	abstract	new	_	_
3-31	355-356	,	_	_	_	_
3-32	357-366	long-term	event[20]	new[20]	_	_
3-33	367-375	missions	event[20]	new[20]	_	_
3-34	376-377	.	_	_	_	_

#Text=At the moment we do not know whether γ radiation only was unable to induce nSMase activation .
4-1	378-380	At	_	_	_	_
4-2	381-384	the	time[21]	new[21]	coref	18-2[135_21]
4-3	385-391	moment	time[21]	new[21]	_	_
4-4	392-394	we	person	acc	ana	5-1
4-5	395-397	do	_	_	_	_
4-6	398-401	not	_	_	_	_
4-7	402-406	know	_	_	_	_
4-8	407-414	whether	_	_	_	_
4-9	415-416	γ	place|abstract[24]	giv|giv[24]	coref|coref	7-4[39_24]|7-4[39_24]
4-10	417-426	radiation	abstract[24]	giv[24]	_	_
4-11	427-431	only	_	_	_	_
4-12	432-435	was	_	_	_	_
4-13	436-442	unable	_	_	_	_
4-14	443-445	to	_	_	_	_
4-15	446-452	induce	_	_	_	_
4-16	453-459	nSMase	abstract[25]	new[25]	_	_
4-17	460-470	activation	abstract[25]	new[25]	_	_
4-18	471-472	.	_	_	_	_

#Text=We show that rMnSOD particles are capable to cross the blood-brain barrier and localize in the midbrain .
5-1	473-475	We	person	giv	ana	9-1
5-2	476-480	show	_	_	_	_
5-3	481-485	that	_	_	_	_
5-4	486-492	rMnSOD	object[27]	new[27]	_	_
5-5	493-502	particles	object[27]	new[27]	_	_
5-6	503-506	are	_	_	_	_
5-7	507-514	capable	_	_	_	_
5-8	515-517	to	_	_	_	_
5-9	518-523	cross	_	_	_	_
5-10	524-527	the	abstract[28]	new[28]	_	_
5-11	528-539	blood-brain	abstract[28]	new[28]	_	_
5-12	540-547	barrier	abstract[28]	new[28]	_	_
5-13	548-551	and	_	_	_	_
5-14	552-560	localize	_	_	_	_
5-15	561-563	in	_	_	_	_
5-16	564-567	the	place[29]	new[29]	_	_
5-17	568-576	midbrain	place[29]	new[29]	_	_
5-18	577-578	.	_	_	_	_

#Text=Here , rMnSOD has the ability to limit radiation-induced damage , such as the loss of neuron number and the alteration of neurofilaments .
6-1	579-583	Here	_	_	_	_
6-2	584-585	,	_	_	_	_
6-3	586-592	rMnSOD	substance	new	coref	8-9
6-4	593-596	has	_	_	_	_
6-5	597-600	the	abstract[31]	new[31]	_	_
6-6	601-608	ability	abstract[31]	new[31]	_	_
6-7	609-611	to	_	_	_	_
6-8	612-617	limit	_	_	_	_
6-9	618-635	radiation-induced	abstract[32]	new[32]	coref	7-6[41_32]
6-10	636-642	damage	abstract[32]	new[32]	_	_
6-11	643-644	,	abstract[32]	new[32]	_	_
6-12	645-649	such	abstract[32]	new[32]	_	_
6-13	650-652	as	abstract[32]	new[32]	_	_
6-14	653-656	the	abstract[32]|abstract[33]	new[32]|new[33]	_	_
6-15	657-661	loss	abstract[32]|abstract[33]	new[32]|new[33]	_	_
6-16	662-664	of	abstract[32]|abstract[33]	new[32]|new[33]	_	_
6-17	665-671	neuron	abstract[32]|abstract[33]|object|abstract[35]	new[32]|new[33]|new|new[35]	_	_
6-18	672-678	number	abstract[32]|abstract[33]|abstract[35]	new[32]|new[33]|new[35]	_	_
6-19	679-682	and	abstract[32]|abstract[33]	new[32]|new[33]	_	_
6-20	683-686	the	abstract[32]|abstract[33]|abstract[36]	new[32]|new[33]|new[36]	_	_
6-21	687-697	alteration	abstract[32]|abstract[33]|abstract[36]	new[32]|new[33]|new[36]	_	_
6-22	698-700	of	abstract[32]|abstract[33]|abstract[36]	new[32]|new[33]|new[36]	_	_
6-23	701-715	neurofilaments	abstract[32]|abstract[33]|abstract[36]|object	new[32]|new[33]|new[36]|new	_	_
6-24	716-717	.	_	_	_	_

#Text=The effect of radiation on brain damage has previously been reported by other authors .
7-1	718-721	The	abstract[38]	giv[38]	coref	8-20[51_38]
7-2	722-728	effect	abstract[38]	giv[38]	_	_
7-3	729-731	of	abstract[38]	giv[38]	_	_
7-4	732-741	radiation	abstract[38]|abstract[39]	giv[38]|giv[39]	ana	8-20[0_39]
7-5	742-744	on	abstract[38]|abstract[39]	giv[38]|giv[39]	_	_
7-6	745-750	brain	abstract[38]|abstract[39]|object|abstract[41]	giv[38]|giv[39]|giv|giv[41]	coref|coref|coref|coref	19-16|21-17[165_41]|19-16|21-17[165_41]
7-7	751-757	damage	abstract[38]|abstract[39]|abstract[41]	giv[38]|giv[39]|giv[41]	_	_
7-8	758-761	has	_	_	_	_
7-9	762-772	previously	_	_	_	_
7-10	773-777	been	_	_	_	_
7-11	778-786	reported	_	_	_	_
7-12	787-789	by	_	_	_	_
7-13	790-795	other	person[42]	new[42]	_	_
7-14	796-803	authors	person[42]	new[42]	_	_
7-15	804-805	.	_	_	_	_

#Text=Although many studies elucidated the radioprotective role of rMnSOD through antioxidant mechanisms in mitochondria , no data exist about its effect on nSMase .
8-1	806-814	Although	_	_	_	_
8-2	815-819	many	abstract[43]	new[43]	_	_
8-3	820-827	studies	abstract[43]	new[43]	_	_
8-4	828-838	elucidated	_	_	_	_
8-5	839-842	the	abstract[44]	giv[44]	coref	13-9[89_44]
8-6	843-858	radioprotective	abstract[44]	giv[44]	_	_
8-7	859-863	role	abstract[44]	giv[44]	_	_
8-8	864-866	of	abstract[44]	giv[44]	_	_
8-9	867-873	rMnSOD	abstract[44]|substance	giv[44]|giv	coref	9-4
8-10	874-881	through	_	_	_	_
8-11	882-893	antioxidant	abstract|abstract[47]	new|new[47]	_	_
8-12	894-904	mechanisms	abstract[47]	new[47]	_	_
8-13	905-907	in	abstract[47]	new[47]	_	_
8-14	908-920	mitochondria	abstract[47]|place	new[47]|new	_	_
8-15	921-922	,	_	_	_	_
8-16	923-925	no	abstract[49]	new[49]	coref	19-4[147_49]
8-17	926-930	data	abstract[49]	new[49]	_	_
8-18	931-936	exist	_	_	_	_
8-19	937-942	about	_	_	_	_
8-20	943-946	its	abstract|abstract[51]	giv|giv[51]	coref|coref|coref|coref	10-20[67_51]|12-12|10-20[67_51]|12-12
8-21	947-953	effect	abstract[51]	giv[51]	_	_
8-22	954-956	on	abstract[51]	giv[51]	_	_
8-23	957-963	nSMase	abstract[51]|abstract	giv[51]|new	coref	10-13
8-24	964-965	.	_	_	_	_

#Text=We show that rMnSOD stimulates nSMase gene and protein expression and enzymatic activity .
9-1	966-968	We	person	giv	ana	14-6
9-2	969-973	show	_	_	_	_
9-3	974-978	that	_	_	_	_
9-4	979-985	rMnSOD	abstract	giv	coref	10-18
9-5	986-996	stimulates	_	_	_	_
9-6	997-1003	nSMase	abstract[55]|abstract[56]|abstract[58]	new[55]|new[56]|new[58]	coref|coref|coref|coref|coref|coref|coref|coref|coref	11-10[76_55]|11-10[77_56]|11-14[79_58]|11-10[76_55]|11-10[77_56]|11-14[79_58]|11-10[76_55]|11-10[77_56]|11-14[79_58]
9-7	1004-1008	gene	abstract[55]|abstract[56]|abstract[58]	new[55]|new[56]|new[58]	_	_
9-8	1009-1012	and	abstract[56]|abstract[58]	new[56]|new[58]	_	_
9-9	1013-1020	protein	abstract[56]|substance|abstract[58]	new[56]|new|new[58]	coref	11-14
9-10	1021-1031	expression	abstract[58]	new[58]	_	_
9-11	1032-1035	and	_	_	_	_
9-12	1036-1045	enzymatic	place|abstract[60]	new|new[60]	coref|coref	17-30[134_60]|17-30[134_60]
9-13	1046-1054	activity	abstract[60]	new[60]	_	_
9-14	1055-1056	.	_	_	_	_

#Text=The study was articulated with the aim of analyzing the response of nSMase in samples in which rMnSOD has a protective effect ( non-pretreated samples ) and in samples in which rMnSOD has a preventive effect ( pretreated samples ) .
10-1	1057-1060	The	abstract[61]	giv[61]	coref	11-4[74_61]
10-2	1061-1066	study	abstract[61]	giv[61]	_	_
10-3	1067-1070	was	_	_	_	_
10-4	1071-1082	articulated	_	_	_	_
10-5	1083-1087	with	_	_	_	_
10-6	1088-1091	the	abstract[62]	giv[62]	_	_
10-7	1092-1095	aim	abstract[62]	giv[62]	_	_
10-8	1096-1098	of	_	_	_	_
10-9	1099-1108	analyzing	_	_	_	_
10-10	1109-1112	the	abstract[63]	new[63]	_	_
10-11	1113-1121	response	abstract[63]	new[63]	_	_
10-12	1122-1124	of	abstract[63]	new[63]	_	_
10-13	1125-1131	nSMase	abstract[63]|abstract	new[63]|giv	coref	13-7
10-14	1132-1134	in	abstract[63]	new[63]	_	_
10-15	1135-1142	samples	abstract[63]|object	new[63]|new	appos	10-24[68_0]
10-16	1143-1145	in	_	_	_	_
10-17	1146-1151	which	_	_	_	_
10-18	1152-1158	rMnSOD	abstract	giv	coref	10-32
10-19	1159-1162	has	_	_	_	_
10-20	1163-1164	a	abstract[67]	giv[67]	coref	10-34[70_67]
10-21	1165-1175	protective	abstract[67]	giv[67]	_	_
10-22	1176-1182	effect	abstract[67]	giv[67]	_	_
10-23	1183-1184	(	_	_	_	_
10-24	1185-1199	non-pretreated	object[68]	giv[68]	appos	10-38[71_68]
10-25	1200-1207	samples	object[68]	giv[68]	_	_
10-26	1208-1209	)	_	_	_	_
10-27	1210-1213	and	_	_	_	_
10-28	1214-1216	in	_	_	_	_
10-29	1217-1224	samples	_	_	_	_
10-30	1225-1227	in	_	_	_	_
10-31	1228-1233	which	_	_	_	_
10-32	1234-1240	rMnSOD	abstract	giv	coref	11-8
10-33	1241-1244	has	_	_	_	_
10-34	1245-1246	a	abstract[70]	giv[70]	coref	11-5[0_70]
10-35	1247-1257	preventive	abstract[70]	giv[70]	_	_
10-36	1258-1264	effect	abstract[70]	giv[70]	_	_
10-37	1265-1266	(	_	_	_	_
10-38	1267-1277	pretreated	object[71]	giv[71]	coref	11-2[72_71]
10-39	1278-1285	samples	object[71]	giv[71]	_	_
10-40	1286-1287	)	_	_	_	_
10-41	1288-1289	.	_	_	_	_

#Text=In samples for protective effect study , rMnSOD increases strongly nSMase gene and protein expression in irradiated samples in a dose-dependent manner .
11-1	1290-1292	In	_	_	_	_
11-2	1293-1300	samples	object[72]	giv[72]	coref	11-17[80_72]
11-3	1301-1304	for	object[72]	giv[72]	_	_
11-4	1305-1315	protective	object[72]|abstract[74]	giv[72]|giv[74]	_	_
11-5	1316-1322	effect	object[72]|abstract|abstract[74]	giv[72]|giv|giv[74]	coref	17-5
11-6	1323-1328	study	object[72]|abstract[74]	giv[72]|giv[74]	_	_
11-7	1329-1330	,	_	_	_	_
11-8	1331-1337	rMnSOD	substance	giv	coref	14-21
11-9	1338-1347	increases	_	_	_	_
11-10	1348-1356	strongly	abstract[76]|abstract[77]	giv[76]|giv[77]	coref|coref|coref|coref	17-8[125_76]|17-8[126_77]|17-8[125_76]|17-8[126_77]
11-11	1357-1363	nSMase	abstract[76]|abstract[77]	giv[76]|giv[77]	_	_
11-12	1364-1368	gene	abstract[76]|abstract[77]	giv[76]|giv[77]	_	_
11-13	1369-1372	and	abstract[77]	giv[77]	_	_
11-14	1373-1380	protein	abstract[77]|substance|abstract[79]	giv[77]|giv|giv[79]	coref|coref|coref|coref	17-11|17-11[128_79]|17-11|17-11[128_79]
11-15	1381-1391	expression	abstract[77]|abstract[79]	giv[77]|giv[79]	_	_
11-16	1392-1394	in	_	_	_	_
11-17	1395-1405	irradiated	object[80]	giv[80]	coref	17-2[121_80]
11-18	1406-1413	samples	object[80]	giv[80]	_	_
11-19	1414-1416	in	object[80]	giv[80]	_	_
11-20	1417-1418	a	object[80]|abstract[81]	giv[80]|new[81]	_	_
11-21	1419-1433	dose-dependent	object[80]|abstract[81]	giv[80]|new[81]	_	_
11-22	1434-1440	manner	object[80]|abstract[81]	giv[80]|new[81]	_	_
11-23	1441-1442	.	_	_	_	_

#Text=Small variations of nSMase enzyme activities are obtained only with high radiation doses .
12-1	1443-1448	Small	abstract[82]	new[82]	_	_
12-2	1449-1459	variations	abstract[82]	new[82]	_	_
12-3	1460-1462	of	abstract[82]	new[82]	_	_
12-4	1463-1469	nSMase	abstract[82]|abstract[84]	new[82]|new[84]	_	_
12-5	1470-1476	enzyme	abstract[82]|substance|abstract[84]	new[82]|new|new[84]	coref	15-26[111_0]
12-6	1477-1487	activities	abstract[82]|abstract[84]	new[82]|new[84]	_	_
12-7	1488-1491	are	_	_	_	_
12-8	1492-1500	obtained	_	_	_	_
12-9	1501-1505	only	_	_	_	_
12-10	1506-1510	with	_	_	_	_
12-11	1511-1515	high	abstract[86]	new[86]	_	_
12-12	1516-1525	radiation	abstract|abstract[86]	giv|new[86]	coref	14-10
12-13	1526-1531	doses	abstract[86]	new[86]	_	_
12-14	1532-1533	.	_	_	_	_

#Text=This observation is relevant , as nSMase plays a crucial role in the regulation of ROS generation and in the maintenance of homeostasis between proapoptotic and prosurvival signals .
13-1	1534-1538	This	abstract[87]	new[87]	_	_
13-2	1539-1550	observation	abstract[87]	new[87]	_	_
13-3	1551-1553	is	_	_	_	_
13-4	1554-1562	relevant	_	_	_	_
13-5	1563-1564	,	_	_	_	_
13-6	1565-1567	as	_	_	_	_
13-7	1568-1574	nSMase	substance	giv	coref	15-7
13-8	1575-1580	plays	_	_	_	_
13-9	1581-1582	a	abstract[89]	giv[89]	_	_
13-10	1583-1590	crucial	abstract[89]	giv[89]	_	_
13-11	1591-1595	role	abstract[89]	giv[89]	_	_
13-12	1596-1598	in	abstract[89]	giv[89]	_	_
13-13	1599-1602	the	abstract[89]|abstract[90]	giv[89]|new[90]	_	_
13-14	1603-1613	regulation	abstract[89]|abstract[90]	giv[89]|new[90]	_	_
13-15	1614-1616	of	abstract[89]|abstract[90]	giv[89]|new[90]	_	_
13-16	1617-1620	ROS	abstract[89]|abstract[90]|substance|abstract[92]	giv[89]|new[90]|new|new[92]	coref|coref	19-25|19-25
13-17	1621-1631	generation	abstract[89]|abstract[90]|abstract[92]	giv[89]|new[90]|new[92]	_	_
13-18	1632-1635	and	_	_	_	_
13-19	1636-1638	in	_	_	_	_
13-20	1639-1642	the	abstract[93]	new[93]	_	_
13-21	1643-1654	maintenance	abstract[93]	new[93]	_	_
13-22	1655-1657	of	abstract[93]	new[93]	_	_
13-23	1658-1669	homeostasis	abstract[93]|abstract[94]	new[93]|new[94]	_	_
13-24	1670-1677	between	abstract[93]|abstract[94]	new[93]|new[94]	_	_
13-25	1678-1690	proapoptotic	abstract[93]|abstract[94]|abstract|abstract[97]	new[93]|new[94]|new|new[97]	_	_
13-26	1691-1694	and	abstract[93]|abstract[94]|abstract[97]	new[93]|new[94]|new[97]	_	_
13-27	1695-1706	prosurvival	abstract[93]|abstract[94]|event|abstract[97]	new[93]|new[94]|new|new[97]	_	_
13-28	1707-1714	signals	abstract[93]|abstract[94]|abstract[97]	new[93]|new[94]|new[97]	_	_
13-29	1715-1716	.	_	_	_	_

#Text=In line with this , we show that highest radiation levels induce significant nSMase responses only in the presence of rMnSOD .
14-1	1717-1719	In	_	_	_	_
14-2	1720-1724	line	_	_	_	_
14-3	1725-1729	with	_	_	_	_
14-4	1730-1734	this	_	_	_	_
14-5	1735-1736	,	_	_	_	_
14-6	1737-1739	we	person	giv	ana	15-17
14-7	1740-1744	show	_	_	_	_
14-8	1745-1749	that	_	_	_	_
14-9	1750-1757	highest	abstract[100]	giv[100]	coref	18-9[137_100]
14-10	1758-1767	radiation	abstract|abstract[100]	giv|giv[100]	coref	19-20
14-11	1768-1774	levels	abstract[100]	giv[100]	_	_
14-12	1775-1781	induce	_	_	_	_
14-13	1782-1793	significant	abstract[101]	new[101]	_	_
14-14	1794-1800	nSMase	abstract[101]	new[101]	_	_
14-15	1801-1810	responses	abstract[101]	new[101]	_	_
14-16	1811-1815	only	abstract[102]	new[102]	_	_
14-17	1816-1818	in	abstract[102]	new[102]	_	_
14-18	1819-1822	the	abstract[102]	new[102]	_	_
14-19	1823-1831	presence	abstract[102]	new[102]	_	_
14-20	1832-1834	of	abstract[102]	new[102]	_	_
14-21	1835-1841	rMnSOD	abstract[102]|substance	new[102]|giv	coref	15-15
14-22	1842-1843	.	_	_	_	_

#Text=Although the present results indicate that nSMase may be required for the action of rMnSOD , we cannot prove the direct action of rMnSOD on this enzyme .
15-1	1844-1852	Although	_	_	_	_
15-2	1853-1856	the	abstract[104]	new[104]	_	_
15-3	1857-1864	present	abstract[104]	new[104]	_	_
15-4	1865-1872	results	abstract[104]	new[104]	_	_
15-5	1873-1881	indicate	_	_	_	_
15-6	1882-1886	that	_	_	_	_
15-7	1887-1893	nSMase	substance	giv	coref	20-6
15-8	1894-1897	may	_	_	_	_
15-9	1898-1900	be	_	_	_	_
15-10	1901-1909	required	_	_	_	_
15-11	1910-1913	for	_	_	_	_
15-12	1914-1917	the	abstract[106]	new[106]	_	_
15-13	1918-1924	action	abstract[106]	new[106]	_	_
15-14	1925-1927	of	abstract[106]	new[106]	_	_
15-15	1928-1934	rMnSOD	abstract[106]|substance	new[106]|giv	coref	15-24[110_0]
15-16	1935-1936	,	_	_	_	_
15-17	1937-1939	we	person	giv	ana	16-2
15-18	1940-1946	cannot	_	_	_	_
15-19	1947-1952	prove	_	_	_	_
15-20	1953-1956	the	abstract[109]	new[109]	ana	16-5[0_109]
15-21	1957-1963	direct	abstract[109]	new[109]	_	_
15-22	1964-1970	action	abstract[109]	new[109]	_	_
15-23	1971-1973	of	abstract[109]	new[109]	_	_
15-24	1974-1980	rMnSOD	abstract[109]|substance[110]	new[109]|giv[110]	coref	16-17[0_110]
15-25	1981-1983	on	abstract[109]|substance[110]	new[109]|giv[110]	_	_
15-26	1984-1988	this	abstract[109]|substance[110]|substance[111]	new[109]|giv[110]|giv[111]	coref	17-31[0_111]
15-27	1989-1995	enzyme	abstract[109]|substance[110]|substance[111]	new[109]|giv[110]|giv[111]	_	_
15-28	1996-1997	.	_	_	_	_

#Text=To our knowledge , this is the first study indicating SMase as a potential effector of rMnSOD during its protection action .
16-1	1998-2000	To	_	_	_	_
16-2	2001-2004	our	person|abstract[113]	giv|new[113]	ana|ana	18-4|18-4
16-3	2005-2014	knowledge	abstract[113]	new[113]	_	_
16-4	2015-2016	,	_	_	_	_
16-5	2017-2021	this	abstract	giv	coref	16-7[115_0]
16-6	2022-2024	is	_	_	_	_
16-7	2025-2028	the	abstract[115]	giv[115]	coref	16-19[120_115]
16-8	2029-2034	first	abstract[115]	giv[115]	_	_
16-9	2035-2040	study	abstract[115]	giv[115]	_	_
16-10	2041-2051	indicating	_	_	_	_
16-11	2052-2057	SMase	abstract	new	_	_
16-12	2058-2060	as	_	_	_	_
16-13	2061-2062	a	_	_	_	_
16-14	2063-2072	potential	_	_	_	_
16-15	2073-2081	effector	_	_	_	_
16-16	2082-2084	of	_	_	_	_
16-17	2085-2091	rMnSOD	substance	giv	ana	16-19
16-18	2092-2098	during	_	_	_	_
16-19	2099-2102	its	substance|abstract[120]	giv|giv[120]	coref|coref|coref|coref	17-4[124_120]|17-26|17-4[124_120]|17-26
16-20	2103-2113	protection	abstract|abstract[120]	new|giv[120]	_	_
16-21	2114-2120	action	abstract[120]	giv[120]	_	_
16-22	2121-2122	.	_	_	_	_

#Text=In samples for preventive effect study , nSMase gene and protein expression is reduced in comparison with the samples in which the protective effect of rMnSOD is studied but the enzyme activity is much higher .
17-1	2123-2125	In	_	_	_	_
17-2	2126-2133	samples	object[121]	giv[121]	coref	17-18[130_121]
17-3	2134-2137	for	object[121]	giv[121]	_	_
17-4	2138-2148	preventive	object[121]|abstract|abstract[124]	giv[121]|new|giv[124]	_	_
17-5	2149-2155	effect	object[121]|abstract|abstract[124]	giv[121]|giv|giv[124]	_	_
17-6	2156-2161	study	object[121]|abstract[124]	giv[121]|giv[124]	_	_
17-7	2162-2163	,	_	_	_	_
17-8	2164-2170	nSMase	abstract[125]|abstract[126]	giv[125]|giv[126]	coref|coref	18-36[0_125]|18-36[0_125]
17-9	2171-2175	gene	abstract[125]|abstract[126]	giv[125]|giv[126]	_	_
17-10	2176-2179	and	abstract[126]	giv[126]	_	_
17-11	2180-2187	protein	abstract[126]|substance|abstract[128]	giv[126]|giv|giv[128]	coref|coref	18-35[146_128]|18-35[146_128]
17-12	2188-2198	expression	abstract[126]|abstract[128]	giv[126]|giv[128]	_	_
17-13	2199-2201	is	_	_	_	_
17-14	2202-2209	reduced	_	_	_	_
17-15	2210-2212	in	_	_	_	_
17-16	2213-2223	comparison	abstract[129]	new[129]	_	_
17-17	2224-2228	with	abstract[129]	new[129]	_	_
17-18	2229-2232	the	abstract[129]|object[130]	new[129]|giv[130]	_	_
17-19	2233-2240	samples	abstract[129]|object[130]	new[129]|giv[130]	_	_
17-20	2241-2243	in	_	_	_	_
17-21	2244-2249	which	_	_	_	_
17-22	2250-2253	the	abstract[131]	new[131]	_	_
17-23	2254-2264	protective	abstract[131]	new[131]	_	_
17-24	2265-2271	effect	abstract[131]	new[131]	_	_
17-25	2272-2274	of	abstract[131]	new[131]	_	_
17-26	2275-2281	rMnSOD	abstract[131]|substance	new[131]|giv	_	_
17-27	2282-2284	is	_	_	_	_
17-28	2285-2292	studied	_	_	_	_
17-29	2293-2296	but	_	_	_	_
17-30	2297-2300	the	abstract[134]	giv[134]	_	_
17-31	2301-2307	enzyme	substance|abstract[134]	giv|giv[134]	_	_
17-32	2308-2316	activity	abstract[134]	giv[134]	_	_
17-33	2317-2319	is	_	_	_	_
17-34	2320-2324	much	_	_	_	_
17-35	2325-2331	higher	_	_	_	_
17-36	2332-2333	.	_	_	_	_

#Text=At this moment we can only speculate why nSMase levels are reduced with pretreatment , a possible explanation being that an extended treatment time could stimulate different metabolic patterns , leading to inhibition of nSMase gene expression .
18-1	2334-2336	At	_	_	_	_
18-2	2337-2341	this	time[135]	giv[135]	_	_
18-3	2342-2348	moment	time[135]	giv[135]	_	_
18-4	2349-2351	we	person	giv	ana	19-6
18-5	2352-2355	can	_	_	_	_
18-6	2356-2360	only	_	_	_	_
18-7	2361-2370	speculate	_	_	_	_
18-8	2371-2374	why	_	_	_	_
18-9	2375-2381	nSMase	abstract[137]	giv[137]	coref	19-35[158_137]
18-10	2382-2388	levels	abstract[137]	giv[137]	_	_
18-11	2389-2392	are	_	_	_	_
18-12	2393-2400	reduced	_	_	_	_
18-13	2401-2405	with	_	_	_	_
18-14	2406-2418	pretreatment	abstract	new	appos	18-16[139_0]
18-15	2419-2420	,	_	_	_	_
18-16	2421-2422	a	abstract[139]	giv[139]	_	_
18-17	2423-2431	possible	abstract[139]	giv[139]	_	_
18-18	2432-2443	explanation	abstract[139]	giv[139]	_	_
18-19	2444-2449	being	_	_	_	_
18-20	2450-2454	that	_	_	_	_
18-21	2455-2457	an	time[141]	new[141]	_	_
18-22	2458-2466	extended	time[141]	new[141]	_	_
18-23	2467-2476	treatment	abstract|time[141]	new|new[141]	_	_
18-24	2477-2481	time	time[141]	new[141]	_	_
18-25	2482-2487	could	_	_	_	_
18-26	2488-2497	stimulate	_	_	_	_
18-27	2498-2507	different	abstract[143]	new[143]	_	_
18-28	2508-2517	metabolic	person|abstract[143]	new|new[143]	_	_
18-29	2518-2526	patterns	abstract[143]	new[143]	_	_
18-30	2527-2528	,	_	_	_	_
18-31	2529-2536	leading	_	_	_	_
18-32	2537-2539	to	_	_	_	_
18-33	2540-2550	inhibition	abstract[144]	new[144]	_	_
18-34	2551-2553	of	abstract[144]	new[144]	_	_
18-35	2554-2560	nSMase	abstract[144]|abstract[146]	new[144]|giv[146]	_	_
18-36	2561-2565	gene	abstract[144]|abstract|abstract[146]	new[144]|giv|giv[146]	_	_
18-37	2566-2576	expression	abstract[144]|abstract[146]	new[144]|giv[146]	_	_
18-38	2577-2578	.	_	_	_	_

#Text=Merging already published data with our findings , it is possible to suggest that in brain tissues exposed to radiation , significant amounts of ROS are generated , stimulating nSMase production to significantly increase MnSOD levels .
19-1	2579-2586	Merging	_	_	_	_
19-2	2587-2594	already	_	_	_	_
19-3	2595-2604	published	_	_	_	_
19-4	2605-2609	data	abstract[147]	giv[147]	_	_
19-5	2610-2614	with	abstract[147]	giv[147]	_	_
19-6	2615-2618	our	abstract[147]|person|abstract[149]	giv[147]|giv|new[149]	_	_
19-7	2619-2627	findings	abstract[147]|abstract[149]	giv[147]|new[149]	_	_
19-8	2628-2629	,	_	_	_	_
19-9	2630-2632	it	abstract	new	cata	19-9[0_151]
19-10	2633-2635	is	_	_	_	_
19-11	2636-2644	possible	_	_	_	_
19-12	2645-2647	to	abstract[151]	new[151]	_	_
19-13	2648-2655	suggest	abstract[151]	new[151]	_	_
19-14	2656-2660	that	abstract[151]	new[151]	_	_
19-15	2661-2663	in	abstract[151]	new[151]	_	_
19-16	2664-2669	brain	abstract[151]|object|object[153]	new[151]|giv|new[153]	_	_
19-17	2670-2677	tissues	abstract[151]|object[153]	new[151]|new[153]	_	_
19-18	2678-2685	exposed	abstract[151]	new[151]	_	_
19-19	2686-2688	to	abstract[151]	new[151]	_	_
19-20	2689-2698	radiation	abstract[151]|abstract	new[151]|giv	_	_
19-21	2699-2700	,	abstract[151]	new[151]	_	_
19-22	2701-2712	significant	abstract[151]|quantity[155]	new[151]|new[155]	_	_
19-23	2713-2720	amounts	abstract[151]|quantity[155]	new[151]|new[155]	_	_
19-24	2721-2723	of	abstract[151]|quantity[155]	new[151]|new[155]	_	_
19-25	2724-2727	ROS	abstract[151]|quantity[155]|substance	new[151]|new[155]|giv	coref	21-5
19-26	2728-2731	are	abstract[151]	new[151]	_	_
19-27	2732-2741	generated	abstract[151]	new[151]	_	_
19-28	2742-2743	,	_	_	_	_
19-29	2744-2755	stimulating	_	_	_	_
19-30	2756-2762	nSMase	abstract[157]	new[157]	ana	20-1[0_157]
19-31	2763-2773	production	abstract[157]	new[157]	_	_
19-32	2774-2776	to	_	_	_	_
19-33	2777-2790	significantly	_	_	_	_
19-34	2791-2799	increase	_	_	_	_
19-35	2800-2805	MnSOD	abstract[158]	giv[158]	coref	21-5[163_158]
19-36	2806-2812	levels	abstract[158]	giv[158]	_	_
19-37	2813-2814	.	_	_	_	_

#Text=This may in turn stimulate nSMase .
20-1	2815-2819	This	abstract	giv	_	_
20-2	2820-2823	may	_	_	_	_
20-3	2824-2826	in	_	_	_	_
20-4	2827-2831	turn	_	_	_	_
20-5	2832-2841	stimulate	_	_	_	_
20-6	2842-2848	nSMase	substance	giv	coref	22-9
20-7	2849-2850	.	_	_	_	_

#Text=At this point , ROS levels may be reduced , with the end result of limiting the damage .
21-1	2851-2853	At	_	_	_	_
21-2	2854-2858	this	event[161]	new[161]	_	_
21-3	2859-2864	point	event[161]	new[161]	_	_
21-4	2865-2866	,	_	_	_	_
21-5	2867-2870	ROS	substance|abstract[163]	giv|giv[163]	_	_
21-6	2871-2877	levels	abstract[163]	giv[163]	_	_
21-7	2878-2881	may	_	_	_	_
21-8	2882-2884	be	_	_	_	_
21-9	2885-2892	reduced	_	_	_	_
21-10	2893-2894	,	_	_	_	_
21-11	2895-2899	with	_	_	_	_
21-12	2900-2903	the	abstract[164]	new[164]	_	_
21-13	2904-2907	end	abstract[164]	new[164]	_	_
21-14	2908-2914	result	abstract[164]	new[164]	_	_
21-15	2915-2917	of	_	_	_	_
21-16	2918-2926	limiting	_	_	_	_
21-17	2927-2930	the	abstract[165]	giv[165]	_	_
21-18	2931-2937	damage	abstract[165]	giv[165]	_	_
21-19	2938-2939	.	_	_	_	_

#Text=In the above described series of events , nSMase may play predominant roles .
22-1	2940-2942	In	_	_	_	_
22-2	2943-2946	the	event[166]	new[166]	_	_
22-3	2947-2952	above	event[166]	new[166]	_	_
22-4	2953-2962	described	event[166]	new[166]	_	_
22-5	2963-2969	series	event[166]	new[166]	_	_
22-6	2970-2972	of	event[166]	new[166]	_	_
22-7	2973-2979	events	event[166]|event	new[166]|new	_	_
22-8	2980-2981	,	_	_	_	_
22-9	2982-2988	nSMase	substance	giv	_	_
22-10	2989-2992	may	_	_	_	_
22-11	2993-2997	play	_	_	_	_
22-12	2998-3009	predominant	abstract[169]	new[169]	_	_
22-13	3010-3015	roles	abstract[169]	new[169]	_	_
22-14	3016-3017	.	_	_	_	_
